信邦制药(002390) - 2025 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2025 was ¥1,421,260,016.43, a decrease of 6.42% compared to the same period last year[3] - Net profit attributable to shareholders was ¥45,128,120.11, down 26.87% year-on-year[3] - The basic earnings per share (EPS) was ¥0.0238, reflecting a decline of 26.77% compared to the previous year[3] - Total operating revenue decreased to ¥4,266,285,288.11 from ¥4,565,355,757.09, a decline of approximately 6.5% year-over-year[21] - Net profit for the period was ¥200,777,172.16, down from ¥232,737,545.03, representing a decrease of approximately 13.7% year-over-year[23] - Earnings per share (EPS) decreased to ¥0.0803 from ¥0.0927, a decline of about 13.0% year-over-year[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,591,850,565.33, a decrease of 4.83% from the end of the previous year[3] - The company's total assets as of September 30, 2025, are 8,591,850,565.33 yuan, a decrease from 9,028,336,478.89 yuan at the beginning of the period, reflecting a reduction of approximately 4.84%[17] - The total current liabilities decreased from 1,806,874,381.49 yuan to 1,379,477,295.60 yuan, a decline of about 23.6%[18] - Total liabilities decreased to ¥1,617,980,920.82 from ¥2,008,414,826.86, a reduction of about 19.4% year-over-year[19] - Total equity attributable to shareholders increased to ¥6,748,968,461.42 from ¥6,710,056,421.59, reflecting a growth of approximately 0.6% year-over-year[19] Cash Flow - Cash flow from operating activities for the year-to-date was ¥461,582,302.36, an increase of 7.38%[3] - Cash flow from operating activities generated ¥461,582,302.36, an increase from ¥429,846,275.78, indicating a growth of approximately 7.4% year-over-year[24] - Cash and cash equivalents at the end of the period are 962,050,214.66 yuan, down from 1,015,515,313.40 yuan, indicating a decrease of approximately 5.26%[16] - The ending cash and cash equivalents balance was $921.17 million, down from $708.27 million in the previous year[25] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 64,321[10] - The largest shareholder, Guizhou Jinyu Investment Partnership, holds 18.52% of the shares, totaling 360,000,000 shares[10] - The total number of shares held by the top 10 unrestricted shareholders amounts to 1,000,000,000 shares, with Guizhou Jinyu Industrial Investment Partnership holding 360,000,000 shares, representing 36% of the total[11] Expenses and Investments - The company reported a significant increase in tax and additional charges, which rose by 70.47% to ¥32,382,910.15[8] - Investment income decreased by 79.53% to ¥266,213.34 due to reduced dividends from investment projects[8] - Research and development expenses increased to ¥4,292,649.11 from ¥3,824,833.20, representing an increase of approximately 12.2% year-over-year[22] - Other income for the period was ¥3,280,069.18, slightly down from ¥3,296,082.51, a decrease of about 0.5% year-over-year[22] Governance Changes - The company has eliminated the supervisory board, transferring its responsibilities to the audit committee of the board of directors, aiming to enhance governance efficiency[13] Borrowings and Financial Activities - The company reported a significant reduction in short-term borrowings from 592,340,496.38 yuan to 306,962,186.01 yuan, a decrease of approximately 48.3%[18] - The total non-current liabilities increased slightly from 160,000,000.00 yuan to 195,800,000.00 yuan, reflecting an increase of about 22.4%[18] - Cash inflow from financing activities totaled $464.80 million, down from $658.29 million in the previous year[25] - Cash outflow from financing activities was $882.72 million, compared to $1.02 billion last year[25] - The net cash flow from financing activities was -$417.92 million, worsening from -$360.12 million year-over-year[25]